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Abstract. In the last decade, a new family of synthetic 
psychostimulant drugs, under the name of cathinones, broke into the 
market. These drugs are mainly consumed by adolescents and 
young adults with recreational purposes, in most cases combined 
with alcoholic drinks. Although a number of works about new 
cathinones have been recently published, none explored the 
consequences of such combination. Because adolescence is a crucial 
period in brain development, we sought to study the effects of the 
combination of mephedrone plus ethanol in adolescent mice, 
focusing on psychostimulant and conditioning effects, as well as on 
neurotoxicity markers. Ethanol increased both locomotor activity 
and conditioned place preference (CPP) induced by mephedrone. 
RNA microarray assays after CPP test yielded significant alterations  
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in neuronal plasticity-related genes and a key role of BDNF and dopamine D3 
receptors in CPP acquisition was found. Ethanol potentiated the oxidative stress as 
well as the decreases in dopaminergic and serotonergic markers in frontal cortex and 
hippocampus respectively, after a binge treatment with mephedrone. Moreover, the 
drug combination impaired spatial learning and memory, as well as neurogenesis to a 
higher extent than mephedrone alone. 
 
Introduction 
 
 Drug abuse is a matter of concern at all life stages but its occurrence at 
earlier ages is especially worrisome, as it can determine the social outcome 
of an individual [1]. While adolescence is a crucial stage in brain 
maturation, experimentation with alcohol and other drugs is common; 
teenagers are not aware of the risks they are taking, as the regions of the 
brain that control impulses are still immature. Substance use during 
adolescence has been associated with alterations in brain structure, 
function, and neurocognition (reviewed by [2]). Moreover, it has been 
reported in studies with humans that drug consumption during adolescence 
increases the likelihood of drug abuse in adulthood [3]. Specifically, 
alterations in the prefrontal regions and limbic systems are thought to 
contribute to increased risk-taking and novelty/sensation seeking behaviors 
[4-6]. 
 Currently, most drug use during adolescence occurs in leisure 
environments, such as dance clubs and parties [7]. Alcohol is omnipresent 
due to its legal drug status [8] while other drugs such as cannabis, cocaine, 
and amphetamine derivatives are often associated with it [9].  
 Moreover, adolescents are less sensitive than adults to the depressant 
effects of alcohol, as well as to the subsequent hangover (reviewed by 
[10]), which facilitates the intake of higher amounts. Numerous studies 
report neurotoxic effects of alcohol itself in consumption models using 
adolescent rodents (reviewed by [11]), mainly leading to impairment in 
memory and visual and verbal tasks [12]. Excitotoxicity and 
neuroinflammation seem to be involved in such deleterious effects [13].  
 During the last decade, a miriad of new designer drugs broke into the 
market. These substances structurally differred from existing banned drugs 
and took profit of this legal loophole to be sold through licit media such as 
the Internet, smart shops, gas stations, etc., always with the disclaimer “not 
for human use” and packaged as “bath salts”, “plant food” or “research 
chemical”. For this reason, these substances where generically called 
“legal highs”. Some of them are currently banned in many countries, but 
Effects of the combination of mephedrone plus ethanol 113 
the pace at which new substances appear exceeds that of the legal 
machinery to illegalize them [14]. 
  Among these new substances, mephedrone (4-methylmethcathinone, 
Meph) is an increasingly consumed synthetic psychostimulant compound, 
which first appeared for sale on the Internet around 2007. It belongs to the 
β-ketoamphetamines group (Fig. 1), also known as cathinones, and is 
commonly taken orally or insufflated [15]. Preclinical studies have shown 
that mephedrone stimulates the release of dopamine (DA), serotonin (5-
HT) and norepinephrine and inhibits their re-uptake in the CNS [16-19]. 
These actions explain the psychostimulation and the effects on perceptions 
reported by human consumers [20]. Experiments in rodents have 
demonstrated the psychostimulant (measured as hyperlocomotion) and 
rewarding (measured as conditioned place preference, CPP) effects of 
mephedrone, which are indicative of its abuse liability [18,21]. 
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Figure 1. Chemical structures of classic amphetamine derivatives, (D-amphetamine, 
methamphetamine and MDMA) cathinone and mephedrone. Please notice the -keto 
group in both cathinones. 
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 Mephedrone is also commonly combined with many other drugs, but 
mainly alcohol [9,22] which, in turn, is the most consumed drug. The study 
of the interactions between drugs of abuse is of interest because 
potentiation of the effects could result in increased abuse liability.  
  In fact, ethanol can effectively potentiate the psychostimulant and 
rewarding effects of another widely abused amphetamine derivative, 3,4-
methylenedioxy-methamphetamine (MDMA) in rodents [23] by a 
combination of both pharmacokinetic and pharmacodynamic interactions. 
Given the resemblance between mephedrone’s mechanism of action and 
that of MDMA [9,18,24], a similar profile should be expected when 
combined with alcohol.  
 Moreover, interaction between drugs could also result in increased 
deleterious effects. Hernández-Rabaza et al. [25] described that 
combination of ethanol with MDMA produces cognitive impairment in 
adolescent rats at doses that do not when administered alone. This 
impairment is accompanied by a decrease in survival of neuronal precursor 
cells as well as a decrease in the presence of mature cells in the dentate 
gyrus (DG) of the hippocampus. Furthermore, Izco et al. [26] found that 
ethanol potentiates MDMA neurotoxicity through the production of 
hydroxyl radicals. 
 These antecedents justify the need for studies about the 
pharmacological and neurotoxicological effects of the combination of 
mephedrone plus ethanol. In this chapter we summarize the works we 
performed on this subject using adolescent mice, owing to the prevalent 
consumption of these drugs in this population group and the reasons 
explained above. Results show increased psychostimulant and rewarding 
effects of the combination, as well as potentiation of the neurotoxicity 
markers and the impaired learning and memory. Such preclinical evidences 
deserve to be investigated in humans in order to, if also occurred in this 
species, transmit a pertinent warning to the population. 
 
1. Psychostimulant effects: Locomotor activity 
 
 In rodents, psychostimulants produce increased locomotor activity; 
therefore measurement of locomotion is a widely employed technique to 
study the acute behavioural effects of new drugs such as mephedrone. The 
technique consists of placing the animals in a cage equipped with infrared 
photocells so that ambulation produces occlusions of the photo beams, 
which are recorded and sent to a computerized system. The more 
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interruption counts (measured over blocks of 10 min during 120 min or 
longer), the higher locomotor activity. Previous works had demonstrated 
that mephedrone induces robust hyperlocomotion [16,18,21] after a single 
injection of 5-25 mg/kg. To assess the effect of the combination with 
ethanol, mice were administered with mephedrone (10 or 25 mg/kg, s.c.) 
alone or combined with ethanol and immediately placed in the activity 
box. Since ethanol, at certain doses, can modify locomotion, it was 
administered at doses reported to not affect basal activity (0.5 or  1 g/kg, 
s.c.; [27,28]).  
 As can be seen in Fig. 2A, the hyperlocomotion induced by 
mephedrone was significantly increased when administered concominantly 
with ethanol [29]. In order to investigate the neurotransmitter responsible 
for such potentiation, the experiments were repeated administering 
previously ketanserin (a serotonin 5-HT2 receptor antagonist) or 
haloperidol (a dopaminergic antagonist with predominant D2 activity). The 
result showed that, although expectedly both antagonists reduced 
locomotor activity, only haloperidol prevented the locomotor enhancement 
of the drug combination, indicating that this occurs through a 
dopaminergic mechanism.  
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Figure 2. A. Locomotor activity of adolescent CD-1 mice treated with ethanol 
(EtOH, 0.5 g/kg, s.c.), mephedrone (Meph, 10 mg/kg, s.c.) or their combination, 
expressed as the cumulative interruptions of the infrared beams (breaks) in the 
activity cage during 120 min. B. Effects of the 5-HT2 antagonist ketanserin (Ket, 1 
mg/kg, i.p.) and D2 antagonist haloperidol (Hal, 0.25 mg/kg), on the hyperlocomotion 
induced by mephedrone (10 mg/kg) and its combination with ethanol. Although both 
antagonists reduced hyperlocomotion, only haloperidol abolished the potentiation by 
ethanol. *P<0.05, **P<0.01, ***P<0.001 vs. saline; ##P<0.01 between the indicated 
groups; ns, non significant differences; one-way ANOVA. Graphs modified from 
[29]. 
David Pubill et al. 116 
  The effects of ethanol in the brain are numerous as it easily crosses 
biological membranes and interacts on several molecular targets (i.e. 
ligand-gated ion channels). One of the main mechanisms by which it is 
capable of increasing hyperlocomotion is the inhibition of GABAergic 
interneurons in the substantia nigra reticulata, which leads to disinhibition 
and increased burst firing of dopamine neurons in the nucleus accumbens, 
but it also directly increases DA release in other areas of mesocortical 
pathways (see [30] for a review). These mechanisms are different from 
those of mephedrone but, in turn, would converge in increased DA release 
and/or desinhibition in certain brain areas, which could explain the 
observed increased effect. 
 
2. Rewarding effects: conditioned place preference (CPP) and 
associated transcriptional changes 
 
 A rewarding stimulus is defined as a stimulus that is considered 
likeable and thus is worthy of being desired and pursued [31]. Rewards 
(both natural and exogenous) trigger two important biological processes: 
 
•  Assignment of a hedonic value. This is defined as how much the 
reward is “pleasurable” or “liked”. 
•  Assignment of an incentive salience, which is defined as a 
motivational value or “wanting” or a given rewarding stimulus [32].  
 
 This distinction is important, since rewarding stimuli modulate 
behavior through an increase in dopamine in the nucleus accumbens 
(NAc), whereas dopamine is not a mediator of the hedonic state elicited by 
a rewarding stimulus [33]. Therefore, the rewarding effects can be 
indicative of its abuse liability. 
 The CPP test is performed in an apparatus composed of three distinct 
areas (two well distinguished compartments communicated by a central 
corridor) separated by manually operated doors [34]. The procedure is 
performed in three phases: pre-conditioning, conditioning and post-
conditioning test. During the pre-conditioning phase (day 1), the mice are 
placed in the middle of the corridor and have free access and roam among 
the compartments of the apparatus. The time spent in each compartment is 
recorded through a zenithal camera and computerized tracking software. 
During the conditioning phase, mice are randomly assigned to receive the 
drug in one of the compartments and the vehicle in the opposite so that 
they receive in alternate days the drug or the vehicle (4 days each 
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treatment), and are confined to the assigned compartment for 30 min. In 
the post-conditioning day, the mice are left to freely wander through both 
compartments, and the time spent in each one is also registered. If the drug 
induced reward, the mouse will prefer to stay in the drug-matched 
compartment, attempting to repeat the experience produced by the drug, so 
an increased time (preference score) with respect to that measured in day 1 
will be recorded.  
 Results showed that the combination of ethanol, at a dose non 
conditioning on its own (0.75 g/kg), increased the preference score induced 
by mephedrone (Fig. 3), which could, in turn, indicate increased abuse 
liability. 
 The mesolimbic pathway is involved in the acquisition of CPP, so 
addictive drugs are expected to evoke synaptic plasticity in the areas that it 
comprises including the NAc, the ventral tegmental area, the hippocampus 
and the medial prefrontal cortex [35]. For this reason, we aimed to 
characterize these changes by determining major transcriptional 
modifications in the ventral striatum (comprising the NAc) after 
completing the whole conditioning process, by means of RNA microarray 
assays. 
 A number of studies using the microarray approach with 
psychostimulants (mainly cocaine, methamphetamine and amphetamine) in 
rodents have been published (reviewed by [36]). More recently, similar 
studies have been carried out with alcohol [37] or heroin and 
methamphetamine [38]. From these studies it is concluded that differential 
gene expression for a given drug depends on many factors such as dose, 
schedule, mode of administration (non-contingent or self-administration), 
studied tissue, animal strain and time of withdrawal or at which timepoint 
the expression is measured. In this study, we focused on the remaining 
expression changes in the ventral striatum 48 h after the end of a 
conditioning treatment, an approach that had not been yet taken for any 
drug of abuse. 
 Results showed significant changes in mRNAs involved in neuronal 
plasticity [29], which is in line with CPP acquisition. These included Syt10 
and Muted, which were only significantly increased in the groups receiving 
mephedrone; and Arpc5, whose expression was increased in all drug-
treated groups and potentiated in the Meph+EtOH group. Its product, 
ARPC5, plays an important role in maintaining the ARP2/3 activity (see 
below). Syt10 encodes synaptotagmin 10, a calcium sensor involved in the 
regulation of neuron size and arborization [39]. Furthermore, the Muted 
gene codifies for a subunit of the BLOC-1 complex, which is involved in 
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the activation of  ARP2/3 [40], whose complex nucleating capability is 
essential for actin remodeling and synaptic plasticity at a pre- and post-
synaptic level  [41,42]. The ARP2/3 complex is associated with F-actin in 
the spinoskeleton core and acts to nucleate new actin filament branches 
from existing actin filaments. It is therefore essential in the activity-
dependent enlargement of dendritic spines. BLOC-1 also plays a key role 
in endosomal trafficking and as such has been found to regulate cell-
surface abundance of the D2 dopamine receptor, the biogenesis and fusion 
of synaptic vesicles, and neurite outgrowth. Similarly, Camkk1, whose 
codified protein plays an important role in actin dynamics, was 
significantly up-regulated. 
 Moreover, the D3 dopamine receptor gene (Drd3) was one of the most 
marked and similarly increased in all drug-treated animals. D3 dopamine 
receptors (D3Rs, see [43] for a review) are a subtype of D2-like receptors 
with both pre- and postsynaptic locations, negatively coupled to adenilyl-
cyclase and acting as autoreceptors modulating dopamine release and/or 
synthesis. D3 receptors are known to be involved in reinforcement and 
reward induced by many drugs, including ethanol [44], cocaine [45, 46],  
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Figure 3. Place preference score (open bars, left axis) and Drd3 mRNA expression 
(dashed bars, right axis) in adolescent mice subjected to CPP being treated according 
to the schedule stated in the text with saline, ethanol (EtOH, 0.75 mg/kg) and 
mephedrone (Meph, 25 mg/kg) plus/minus ethanol. *P<0.05, **P<0.01, ***P<0.001 
vs. saline; #P<0.05 vs. Meph.; one-way ANOVA. Data taken from [29]. 
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morphine [47] and methamphetamine [48]. They are mainly localized in 
limbic brain regions, especially the nucleus accumbens [49]. Ethanol, 
morphine or cocaine, are also capable of upregulating Drd3 mRNA in 
rodents [50-52] and in human addicts [53]. 
 Based on these antecedents, we tested whether blocking D3 receptors 
with the D3 antagonist SB-277011A affected CPP and Drd3 up-regulation 
induced by Meph and its combination with ethanol. The antagonist was 
given before the drugs each conditioning session, and was capable of 
completely blocking mephedrone-induced CPP and Drd3 mRNA            
up-regulation (Ref BJP). The fact that Drd3 was also increased in the 
EtOH group, which did not show CPP at the dose used, suggests that it is 
not the sole player in establishing conditioning but that other partners, 
probably among the other modified genes reported above, are needed.  
 However, due to the robust blockade obtained with the D3 antagonist, 
we further explored the mechanisms involved in mephedrone-induced CPP 
and Drd3 up-regulation. BDNF controls dopamine D3 receptor expression 
[54] and its levels are increased by psychostimulants [55]. In fact, BDNF 
and D3 receptors share common pathways in their respective signalling 
cascades (reviewed by [56]). Furthermore, Le Foll et al. [51] described that 
Drd3 mRNA and D3 receptor binding are significantly increased after a 
single dose of cocaine and preceded by a transient increase in BDNF 
mRNA. Thus increased BDNF expression has been suggested to alter the 
response to drug-associated cues by affecting the D3 receptors in the 
nucleus accumbens.  
 In order to assess a possible role of BDNF in the effects of 
mephedrone, we measured its mRNA in medial prefrontal cortex after an 
acute dose of this cathinone (25 mg/kg), finding a progressive increase 
along 4 h after the injection [29] up to two-fold. Further, the role of BDNF 
was pharmacologically confirmed by using ANA-12, a selective trkB 
(BDNF receptor) antagonist. When administered before the drugs each 
conditioning session, ANA-12 blocked both CPP and Drd3 up-regulation 
induced by mephedone. This confirms that D3 receptor differential 
expression can be mediated by BDNF, and points to the fact that blocking 
their signalling can reduce the rewarding properties of mephedrone.  
 
3. Dopaminergic and serotonergic toxicity 
 
 Neurotoxicity of amphetamine derivatives (i.e. methamphetamine, 
MDMA) is a matter of concern and has been subject of a great amount of 
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research. This led to undertake studies exploring a possible neurotoxic 
effect of new drugs such as mephedrone in rodents [57,58]. Reported 
research evidences the need to perform neurotoxicity assays under 
different administration schedules and controlled room temperature. Our 
group described mephedrone neurotoxicity using dosing schedules which 
agreed with mephedrone pharmacokinetics and exploring cerebral areas 
others than the striatum [59,60]. From these antecedents and in order to 
investigate the effects when combined with ethanol, we chose 
administering four doses of 25 mg/kg (s.c.) in one day, every two hours, 
given alone or combined with ethanol at changing doses calculated to 
cause blood ethanol concentration leveling around 1.5 g/L during the 
whole duration of the treatment [61]. Also, during the treatment, room 
temperature was set at 26  2 ºC, at which mephedrone has been reported 
to induce signs of neurotoxicity [60], in order to reproduce the common 
hot conditions found in crowded dance clubs.   
 Decreases in the density of monoamine transporters and synthetic 
enzymes are characteristic markers of amphetamines’ neurotoxicity. Thus, 
we measured the density of transporters by means of radioligand binding 
experiments and the enzymes by Western blotting in brain areas of mice 7 
days after receiving the above treatment. The results showed that, as 
expected, mephedrone reduced the levels of dopamine transporters (DAT, 
binding of [
3
H]WIN 35428) in the frontal cortex and of serotonin 
transporters (SERT, binding of [
3
H]paroxetine) in the hippocampus              
(Fig. 4A, B), while DAT in the striatum and SERT in the frontal cortex 
were unaffected [61]. Accordingly, the levels of tyrosine hydroxylase (TH) 
and tryptophan hydroxylase (TPH) were reduced in frontal cortex and 
hippocampus, respectively. Moreover, the decreases were higher when 
mephedrone was combined with ethanol, which indicates that the 
combination potentiates the dopaminergic and serotonergic toxicities of 
these drugs. 
  
4. Oxidative stress 
 
 Oxidative stress has been classically associated with amphetamines’ 
neurotoxicity and previous evidence indicates that this also occurs with 
mephedrone. Therefore lipid peroxidation and oxidative stress-related 
enzymes were assessed in frontal cortex and hippocampus from mice 
sacrificed 24 h after receiving the above treatment.   
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Figure 4. Assessment of the levels of serotonin (SERT) and dopamine (DAT) 
transporters (panels A and B) and lipid peroxidation measured as levels of 
malondialdehyde (MDA, panels C and D) in hippocampus and frontal cortex, 
respectively. Adolescent CD-1 mice were treated with either saline, ethanol, 
mephedrone, or their combination, following the schedule described above. 
Monoamine transporters were measured 7 days after the treatment, while MDA was 
determined in samples from mice killed 24 h after the last dose. Values represent 
means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. saline; #P < 0.05, ##P < 0.01 
between the indicated groups. Data obtained from [61]. 
 
 Lipid peroxidation was measured as a raise in the MDA levels, a 
general indicator of the decomposition of polyunsaturated fatty acids. 
Mephedrone alone only significantly increased MDA levels in the 
hippocampus. By contrast, the combination of mephedrone with ethanol 
caused higher and significant increases in the levels of MDA (Fig. 4B, C).   
 As far as antioxidant activity-related enzymes is concerned, glutathion 
peroxydase and catalase were significantly and similarly overexpressed 
(around two-fold increase) in both mephedrone-treated groups [61]. 
Regarding superoxide dismutase expression, there was also an increase 
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(around 85%), although statistically non-significant in both mephedrone-
treated groups. This indicates that an antioxidant response is triggered after 
the treatment with mephedrone plus/minus ethanol, which is not further 
increased in the mephedrone+ethanol group. When comparing these with 
the lipid peroxidation data, it can be suggested that there is a potentiation 
in oxidative stress-related damage in the mephedrone+ethanol group, 
where the effects of the drug combination exceed the antioxidant response 
leading to increased effect of generated ROS. 
 
5. Effects on learning and spatial memory 
 
 Neuronal oxidative stress and serotonergic impairment can have 
consequences on learning and memory, so we investigated the performance 
of mice in the Morris water maze seven days after receiving the treatments 
stated above [61]. The maze consists of a circular pool filled with water 
(22 ± 1º C) and rendered opaque by the addition of a non-toxic latex 
solution. The pool must be in an isolated room and black curtains are 
closed around it to suppress room cues [62]. Four positions around the 
edge of the tank are designated as north (N), south (S), east (E), and west 
(W) and also define the division of the tank into four quadrants: NE, SE, 
SW, and NW, providing alternative start positions. Four extra-maze distal 
cues are located equidistantly around the pool, labeling the N, S, E and W 
locations. A Plexiglas escape platform is submerged in the water so that it 
is not visible at the surface level.  
 The test measures the ability of each mouse to learn the position of the 
hidden platform (always the same) in relation to the distal cues, after 
several training sessions being placed in the water from an alternate semi-
random set of start locations. The path taken by each mouse and the escape 
latency (the time needed by each mouse to find the platform, in s) is 
recorded by a zenithal video camera connected to a computer running a 
tracking software. Mice were trained throughout six days, receiving five 
trials per day [61]. A trial was started by placing the mouse in the desired 
start position of the pool, facing the tank wall. The mice were allowed to 
swim to the hidden platform, and the escape latency was determined. If an 
animal did not escape within 60 s, it was gently placed on the platform or 
guided to it. The mice were allowed to rest for 30 s (inter-trial interval) on 
the platform (even those that failed to locate it). Then, learning curves of 
the four treatment groups were plotted as the time-course evolution of the 
latency to reach the hidden platform. To assess reference memory at the 
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end of learning, a probe trial (free swimming without platform for 60 s), 
was given 24 h after the last training session. Different parameters of each 
mouse’s performance are analyzed: the total time and distance spent 
swimming in each quadrant, entries in each quadrant and time elapsed 
(latency) until the mouse first reached the target zone (area where the 
platform was formerly located). 
 The learning curves of the four treatment groups (saline, mephedrone, 
ethanol and mephedrone+ethanol) showed that the mice pre-treated with 
saline or ethanol reduced the latency along the training days, which 
indicates learning, while those pre-treated with mephedrone and, 
moreover, those that received mephedrone+ethanol did not show such a 
progression, suggesting learning impairment [61]. 
 As far as memory is concerned, in the probe trial, the mice that had 
received mephedrone and those pre-treated with the drug combination 
spent significantly less time than the saline and ethanol groups in the 
quadrant where the platform was located (Fig. 5), pointing to impaired 
memory. In this case, no significant differences were found between 
mephedrone and mephedrone+ethanol groups. As spatial memory is 
mainly attributable to hippocampal activity, the serotonergic impairment 
previously detected in the hippocampus could account for this memory 
affection. 
 
6. Effects on hippocampal neurogenesis 
 
 The subgranular zone of the dentate gyrus (DG) of the hippocampus is 
one of the two regions in the adult brain containing neural stem cells that 
underlie adult neurogenesis [63,64]. It is currently accepted that 
hippocampal structure and function relies upon hippocampal stem cells and 
constitutive neurogenesis [65,66]. The thousands of new cells added daily 
to the DG suggest its role in hippocampal structure and/or function [67]. 
Neurogenesis consists of four main components: neural stem cells 
proliferation followed by newborn cell migration, differentiation, and 
survival. 
 It has been widely suggested that the generation of new neurons is 
implicated in correct learning and memory processes, including MWM 
performance in rodents [68]. Furthermore, neurotoxic processes are 
closely related to a decrease in cell proliferation and an increase in cell 
death. Serotonin input to the hippocampus positively regulates adult 
neurogenesis [69]. In this sense, serotonin reuptake inhibitors increase 
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hippocampal neurogenesis [70] while repeated exposure to high doses of 
MDMA, which produces serotonergic neurotoxicity, causes the opposite 
effect [71]. 
 Neurogenesis from the granular layer of the DG is impaired following 
treatment with ethanol [72-74] and adolescents are more sensitive than 
adults to such effects [75]. Therefore, combination of alcohol with 
serotonergic amphetamines could account for an increased deleterious 
effect on neurogenesis. In fact, Hernández-Rabaza el al. [25] described that 
the cognitive impairment produced by the combination of MDMA with 
ethanol in adolescent rats was accompanied by a decrease in survival of 
neuronal precursor cells as well as a decrease in the presence of mature 
cells in the DG of the hippocampus.  
 With these antecedents, the effects of the combination of ethanol with 
mephedrone on neurogenesis deserved to be studied. For this reason, the 
mice that were tested in the MWM had received two injections of bromo-
deoxyuridine (BrdU) 2 and 12 h after the last dose of treatment [61]. BrdU 
is a thymidine analog that is incorporated into cells in place of a thymine 
base pair as the cell undergoes DNA replication during the S phase of the 
mitotic cell cycle and is transmitted to the newly generated cells. BrdU can 
be labeled with specific antibodies so that it can be used as a measure of 
cell proliferation. 
 Twenty eight days after receiving the binge drug treatment (14 days 
post-MWM test) the animals were sacrificed and their sectioned brains 
were stained for BrdU and NeuN (a marker of neurons) and visualized 
under a confocal microscope. The cells colocalizing the two labels 
(newborn neurons) were counted and the results from the different 
treatment groups compared. A significant decrease in newly formed cells 
in the DG of mice administered with mephedrone and 
mephedrone+ethanol was found, with respect to saline. Furthermore, the 
group treated with the drug combination showed significantly less new 
neurons than that treated with mephedrone alone, indicating an increased 
deleterious effect of the combination. BrdU count in animals treated with 
ethanol alone was unaffected with respect to saline (Fig. 5B). Moreover, 
there was a good correlation between the total amount of new cells and 
overall MWM performance (Fig. 5). 
 5-HT input to the hippocampus positively regulates adult neurogenesis 
[69]. In this sense, 5-HT reuptake inhibitors increase hippocampal 
neurogenesis [70]. Furthermore, repeated exposure to high doses                       
of MDMA causes the opposite effect [71]. Similarly to what occurs with  
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Figure 5. Effects of treatment with saline, ethanol, mephedrone or their combination 
on spatial memory and hippocampal neurogenesis. Adolescent mice were treated as 
described above and received two injections of BrdU. Seven days after, they were 
submitted to the Morris water maze paradigm, consisting of 6 days of training and    
1 day of trial. Dashed bars represent, on the probe test day (day 7), the latency to first 
reach the area where the platform had been located during the training period. The 
animals were killed 28 days after the treatment and their brains were fixed, sliced and 
immunostained for BrdU (proliferating cells) and NeuN (neuronal marker). Open 
bars show overall quantification and means of BrdU-positive neurons per area. Data 
are means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. saline; #P < 0.05 vs.  
mephedrone group. Data obtained from [61]  
 
mephedrone in the present study, MDMA is known to produce a depletion 
of serotonergic markers in the hippocampus 7 days after repeated treatment 
[76]; this 5-HT depletion can, in turn, cause decreased cell survival in the 
dentate gyrus [77].   
 
7. Conclusions 
 
 To sum up, the co-administration of ethanol to adolescent mice 
potentiates the psychostimulant and conditioning effects of mephedrone, 
but also its neurotoxic properties. 
 All this suggests an increased risk if translated to humans. On the one 
hand, enhancement of psychostimulant and rewarding effects could 
promote increased abuse liability and addiction-related disorders whereas, 
on the other hand, binge abuse of the drug combination could carry more 
severe neural damage involving dopaminergic and serotonergic 
impairment, decreased neurogenesis and cognitive deficits. 
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 The preclinical studies reviewed here are the first performed on 
polyabuse with cathinones, which are becoming increasingly popular 
among adolescents. Their importance lies in that cathinones are mostly 
used in combination with alcoholic drinks, and are generally regarded as 
“safe” drugs. Thus, an experimental-based warning concerning the risks 
regarding the combined consumption of these drugs should be conveyed to 
the population at large. Nonetheless, although adolescent brains are 
exceptionally vulnerable, studies in adult mice would be necessary to 
determine whether adults could be also susceptible to these effects.  
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